Open-Label, Randomized, and Multicenter Phase III Clinical Trial Comparing Immunogenicity of [Hepatitis B vaccine recombinant] Double-Dose (40 microg at S0, S4 and S24), Versus Standard Dose Vaccination (20 microg at S0, S4 and S24), Against Hepatitis B Virus in HIV-1-Infected Patients Without Any Previous Immune Response After Primary Immunization Plus One Single Boost.
Phase of Trial: Phase III
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Pharmacodynamics
- Acronyms B-BOOST
- 07 Jun 2017 Biomarkers information updated
- 06 Jul 2012 Additional lead trial centre (French National Institute for Health and Medical Research) identified as reported by ClinicalTrials.gov.
- 18 Jan 2012 Planned end date changed from 1 Nov 2010 to 1 Feb 2013 as reported by ClinicalTrials.gov.